Clinical Trial: MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measl

Brief Summary: This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian cancer cells.